Licong Liang

641 total citations · 1 hit paper
21 papers, 419 citations indexed

About

Licong Liang is a scholar working on Hepatology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Licong Liang has authored 21 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 6 papers in Pathology and Forensic Medicine and 4 papers in Molecular Biology. Recurrent topics in Licong Liang's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer Mechanisms and Therapy (5 papers) and Liver Disease Diagnosis and Treatment (3 papers). Licong Liang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer Mechanisms and Therapy (5 papers) and Liver Disease Diagnosis and Treatment (3 papers). Licong Liang collaborates with scholars based in China, United States and Hong Kong. Licong Liang's co-authors include Wensou Huang, Yongjian Guo, Liteng Lin, Jingjun Huang, Kangshun Zhu, Mingyue Cai, Bihui Cao, Jingwen Zhou, Yongcheng An and Ye Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Frontiers in Immunology.

In The Last Decade

Licong Liang

19 papers receiving 418 citations

Hit Papers

Transarterial Chemoembolization Combined With Lenvatinib ... 2022 2026 2023 2024 2022 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
    2022 117 citations Mingyue Cai, Wensou Huang et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Licong Liang China 9 205 112 99 88 84 21 419
Christine Dela Cruz United States 5 363 1.8× 153 1.4× 131 1.3× 131 1.5× 85 1.0× 14 477
Sui Peng China 11 215 1.0× 91 0.8× 74 0.7× 44 0.5× 129 1.5× 24 402
Imane El Dika United States 13 178 0.9× 214 1.9× 69 0.7× 86 1.0× 145 1.7× 30 573
Bowen Zhu China 10 360 1.8× 174 1.6× 142 1.4× 155 1.8× 104 1.2× 22 614
Yunxing Shi China 10 145 0.7× 68 0.6× 56 0.6× 62 0.7× 123 1.5× 17 386
Xiaoju Shi China 13 89 0.4× 128 1.1× 88 0.9× 33 0.4× 69 0.8× 35 415
Tongguo Si China 13 126 0.6× 153 1.4× 38 0.4× 50 0.6× 90 1.1× 29 405
Yun Hua Lee Singapore 5 259 1.3× 291 2.6× 132 1.3× 52 0.6× 65 0.8× 5 571
Binghai Zhou China 13 97 0.5× 129 1.2× 67 0.7× 44 0.5× 175 2.1× 24 499
Dalu Kong China 12 131 0.6× 138 1.2× 82 0.8× 68 0.8× 141 1.7× 33 414

Countries citing papers authored by Licong Liang

Since Specialization
Citations

This map shows the geographic impact of Licong Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Licong Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Licong Liang more than expected).

Fields of papers citing papers by Licong Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Licong Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Licong Liang. The network helps show where Licong Liang may publish in the future.

Co-authorship network of co-authors of Licong Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Licong Liang. A scholar is included among the top collaborators of Licong Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Licong Liang. Licong Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yue, Xiaobin Wang, Ye Chen, et al.. (2025). Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 186. 118046–118046. 1 indexed citations
2.
3.
Li, Rui, Zhile Liu, Wensou Huang, et al.. (2024). Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. Cellular and Molecular Gastroenterology and Hepatology. 18(4). 101379–101379. 2 indexed citations
4.
Cai, Mingyue, Wensou Huang, Wei Liang, et al.. (2024). Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study. Liver International. 44(4). 920–930. 13 indexed citations
5.
6.
Jiang, Anna, et al.. (2024). Multimodal optical imaging of iris flocculi in three consecutive generations: a case report. Frontiers in Medicine. 11. 1369884–1369884.
7.
Chen, Qin, et al.. (2024). Epidemiological and clinical characteristics of open globe injuries in Southwest China. Frontiers in Medicine. 11. 1303683–1303683. 4 indexed citations
8.
Liu, Mingyu, Lulu Xie, Yuying Zhang, et al.. (2023). Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death and Disease. 14(1). 25–25. 18 indexed citations
9.
Xie, Lulu, Mingyu Liu, Mingyue Cai, et al.. (2023). Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 159. 114254–114254. 15 indexed citations
10.
Liu, Wei, Qin Chen, Libo Zhang, et al.. (2023). Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis. Investigative Ophthalmology & Visual Science. 64(10). 30–30. 8 indexed citations
11.
Jiang, Xiaoshuang, Mengxi Shen, Licong Liang, Philip J. Rosenfeld, & Fang Lü. (2023). Severe retinal hemorrhages at various levels with a serous retinal detachment in a pediatric patient with aplastic anemia–A case report. Frontiers in Medicine. 10. 1051089–1051089.
12.
13.
Bu, Shaochong, et al.. (2023). Visual Acuity-Related Outer Retinal Structural Parameters on Swept Source Optical Coherence Tomography and Angiography in XLRS Patients and Carriers. Translational Vision Science & Technology. 12(12). 7–7. 1 indexed citations
14.
Cai, Mingyue, Wensou Huang, Jingjun Huang, et al.. (2022). Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Frontiers in Immunology. 13. 117 indexed citations breakdown →
15.
Huang, Jingjun, Wensou Huang, Meixiao Zhan, et al.. (2021). Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 8. 1445–1458. 27 indexed citations
16.
Liang, Licong, et al.. (2021). Persistent anterior tunica vasculosa lentis in multisystemic smooth muscle dysfunction syndrome. Medicine. 100(22). e26094–e26094. 3 indexed citations
17.
Liang, Licong, et al.. (2021). Case Report: A Case of Cotton-Wool Spots After Intravitreal Injection of Conbercept in an Infant With Incontinentia Pigmenti. Frontiers in Medicine. 8. 761398–761398. 3 indexed citations
18.
Cao, Bihui, Manting Liu, Jingjun Huang, et al.. (2021). Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. International Journal of Biological Sciences. 17(14). 3850–3861. 71 indexed citations
19.
Lin, Liteng, Rui Li, Jingjun Huang, et al.. (2020). Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation. Advanced Science. 7(7). 1903138–1903138. 80 indexed citations
20.
Guo, Yongjian, Liteng Lin, Jingjun Huang, et al.. (2019). LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomedicine & Pharmacotherapy. 118. 109272–109272. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine Dela Cruz Breakdown of academic impact, for papers by Sui Peng Breakdown of academic impact, for papers by Imane El Dika Breakdown of academic impact, for papers by Bowen Zhu Breakdown of academic impact, for papers by Yunxing Shi Breakdown of academic impact, for papers by Xiaoju Shi Breakdown of academic impact, for papers by Tongguo Si Breakdown of academic impact, for papers by Yun Hua Lee Breakdown of academic impact, for papers by Binghai Zhou Breakdown of academic impact, for papers by Dalu Kong
Rankless by CCL
2026